Who is sponsoring NCT05927337?

NCT05927337 is sponsored by University Medical Centre Ljubljana.

What drugs are being tested in NCT05927337?

Interventions in NCT05927337: Cognitive Behavioral Therapy (CBT) for managing Obesity.

What condition does NCT05927337 study?

NCT05927337 studies Chronic Kidney Diseases, Obesity, Overweight.

Is NCT05927337 still recruiting?

NCT05927337 is currently status unknown. Last updated 3 July 2023.

Last reviewed 2023-07-03 · How we verify

NCT05927337

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cognitive-Behavioral Therapy for Managing Obesity in People With Chronic Kidney Disease

Status unknown NA Last updated 3 July 2023

What this trial tests

NA trial testing Cognitive Behavioral Therapy (CBT) for managing Obesity in Chronic Kidney Diseases in 60 participants. Status unknown.

Timeline

1 May 2023

Primary endpoint
31 August 2025

31 December 2025

Quick facts

Lead sponsor	University Medical Centre Ljubljana
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 May 2023
Primary completion	31 August 2025
Estimated completion	31 December 2025
Sites	1 location across Slovenia

Drugs / interventions tested

Cognitive Behavioral Therapy (CBT) for managing Obesity

Conditions studied

Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →
Obesity — all drugs for Obesity →
Overweight — all drugs for Overweight →

Sponsor

University Medical Centre Ljubljana

Who can join

18 and older, any sex, with Chronic Kidney Diseases or Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the study Cognitive-Behavioral Therapy (CBT) for Managing Obesity in People with Chronic Kidney Disease (CKD) the investigators will test whether CBT programme is effective for weight loss and weight maintenance after the treatment programme in patients with obesity, chronic kidney disease and proteinuria. The investigators will test whether subjects randomised to the intervention group and receiving cognitive behavioural therapy can achieve greater weight loss and proteinuria reduction in chronic kidney disease than subjects randomised to the control group and not receiving cognitive behavioural therapy. Both groups of subjects will be counselled by a dietician to improve their diet and reduce excess weight and to kinesiologist for advice on physical activity.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Cognitive behavioral therapy for managing obesity in patients with chronic kidney disease: Study protocol for a randomized controlled trial.
Kurnik Mesarič K, Kodrič J, Logar Zakrajšek B, Pernat AM, et al · · 2023 · cited 1× · PMID 38074489 · DOI 10.1016/j.conctc.2023.101236
Lost and not found: randomized controlled trial of cognitive behavioral therapy for weight-loss in patients with chronic kidney disease.
Kurnik Mesarič K, Kodrič J, Bogataj Š, Marn Pernat A, et al · · 2025 · PMID 40537570 · DOI 10.1007/s10865-025-00583-w

Verify or expand the search:

Other recruiting trials for Chronic Kidney Diseases

Currently open trials in the same condition.

NCT06593392 — Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus · Phase 2 · recruiting
NCT07358572 — Eye-Brain-Kidney in CKD · recruiting
NCT06463483 — Automated Insulin Delivery in Adults With Advanced Kidney Disease · NA · recruiting
NCT06927024 — Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD) · NA · recruiting
NCT07115953 — Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension · NA · recruiting

Other University Medical Centre Ljubljana trials

Trials by the same sponsor.

NCT07466472 — Image-Guided Central Catheter Insertion With Concurrent Assessment of Vascular Wall Integrity · not yet recruiting
NCT07446244 — Catheter Ablation of Advanced Forms of Atrial Fibrillation · NA · enrolling by invitation
NCT07109076 — Effect of Immediate Skin-to-Skin Contact on Neonatal Heart Rate Variability After Cesarean Secton · NA · recruiting
NCT07354880 — Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease · Phase 4 · not yet recruiting
NCT07496736 — Post-exposure Influenza Prophylaxis in a Hospital Setting · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05927337 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Medical Centre Ljubljana
Last refreshed: 3 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05927337.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing